Bristol-Myers Squibb to Post FY2025 Earnings of $7.06 Per Share, William Blair Forecasts (NYSE:BMY)

Bristol-Myers Squibb (NYSE:BMY - Free Report) - Equities research analysts at William Blair raised their FY2025 earnings per share (EPS) estimates for Bristol-Myers Squibb in a research note issued to investors on Monday, April 1st. William Blair analyst M. Phipps now anticipates that the biopharmaceutical company will post earnings of $7.06 per share for the year, up from their prior forecast of $6.96. William Blair has a "Market Perform" rating on the stock. The consensus estimate for Bristol-Myers Squibb's current full-year earnings is $6.61 per share.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last released its earnings results on Friday, February 2nd. The biopharmaceutical company reported $1.70 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.55 by $0.15. The firm had revenue of $11.48 billion for the quarter, compared to analyst estimates of $11.19 billion. Bristol-Myers Squibb had a return on equity of 50.95% and a net margin of 17.83%. Bristol-Myers Squibb's revenue was up .6% compared to the same quarter last year. During the same period in the previous year, the company earned $1.82 earnings per share.

A number of other equities analysts have also recently weighed in on the company. Bank of America cut Bristol-Myers Squibb from a "buy" rating to a "neutral" rating and dropped their price target for the stock from $68.00 to $60.00 in a research note on Wednesday, January 3rd. Redburn Atlantic cut Bristol-Myers Squibb from a "buy" rating to a "neutral" rating and dropped their price target for the stock from $77.00 to $54.00 in a research note on Tuesday, February 6th. StockNews.com raised Bristol-Myers Squibb from a "buy" rating to a "strong-buy" rating in a research note on Friday, March 1st. Wells Fargo & Company lowered their target price on Bristol-Myers Squibb from $58.00 to $51.00 and set an "equal weight" rating on the stock in a research note on Tuesday, February 6th. Finally, Societe Generale cut Bristol-Myers Squibb from a "buy" rating to a "hold" rating in a research note on Monday, March 11th. One investment analyst has rated the stock with a sell rating, fifteen have assigned a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $61.12.

Bristol-Myers Squibb Trading Down 0.3 %

BMY traded down $0.18 during trading on Thursday, reaching $51.40. The company had a trading volume of 10,025,496 shares, compared to its average volume of 16,469,240. The firm's 50-day simple moving average is $51.12 and its 200 day simple moving average is $52.21. The company has a market cap of $104.18 billion, a price-to-earnings ratio of 13.32, a PEG ratio of 1.59 and a beta of 0.39. Bristol-Myers Squibb has a 12-month low of $47.58 and a 12-month high of $71.07. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.31 and a current ratio of 1.43.

Institutional Investors Weigh In On Bristol-Myers Squibb

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. OFI Invest Asset Management bought a new stake in shares of Bristol-Myers Squibb during the third quarter valued at approximately $25,000. True Wealth Design LLC acquired a new position in Bristol-Myers Squibb in the fourth quarter worth $26,000. Milestone Investment Advisors LLC acquired a new position in shares of Bristol-Myers Squibb during the third quarter valued at $27,000. Northwest Financial Advisors acquired a new position in shares of Bristol-Myers Squibb during the fourth quarter valued at $27,000. Finally, Coppell Advisory Solutions LLC acquired a new position in shares of Bristol-Myers Squibb during the second quarter valued at $28,000. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Bristol-Myers Squibb declared that its board has authorized a stock repurchase plan on Thursday, December 7th that authorizes the company to repurchase $3.00 billion in outstanding shares. This repurchase authorization authorizes the biopharmaceutical company to buy up to 2.9% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company's management believes its stock is undervalued.

Bristol-Myers Squibb Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, May 1st. Investors of record on Friday, April 5th will be issued a $0.60 dividend. The ex-dividend date of this dividend is Thursday, April 4th. This represents a $2.40 annualized dividend and a yield of 4.67%. Bristol-Myers Squibb's dividend payout ratio (DPR) is currently 62.18%.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.